119 HR 1143 IH: Medicare IVIG Access Enhancement Act of 2025 U.S. House of Representatives 2025-02-07 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.

I119th CONGRESS1st SessionH. R. 1143IN THE HOUSE OF REPRESENTATIVESFebruary 7, 2025Mr. Smith of Nebraska (for himself and Mr. Garamendi) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concernedA BILLTo amend title XVIII of the Social Security Act to expand coverage of the in-home administration of intravenous immune globulin under the Medicare program.

1.

Short title

This Act may be cited as the Medicare IVIG Access Enhancement Act of 2025.

2.

Expanding coverage of the in-home administration of intravenous immune globulin under the Medicare program

(a)

In general

Section 1861 of the Social Security Act (42 U.S.C. 1395x) is amended— (1)in subsection (s)(2)(Z), by inserting (and, beginning January 1, 2027, for the treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy) after primary immune deficiency diseases; and (2)in subsection (zz), by inserting (or, beginning January 1, 2027, with diagnosed chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy) after primary immune deficiency disease. (b)

Authority for variance in payments

Section 1842(o)(8) of the Social Security Act (42 U.S.C. 1395u(o)(8)) is amended by inserting and may vary depending on whether such administration is related to treatment of a primary immune deficiency disease or the treatment of chronic inflammatory demyelinating polyneuropathy or multifocal motor neuropathy (as determined appropriate by the Secretary through notice and comment rulemaking) after of 2012.